Market: NASD |
Currency: USD
Address: 3525 Del Mar Heights Road
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Show more
📈 Dermata Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$10.00
-
Upside/Downside from Analyst Target:
87.62%
-
Broker Call:
2
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
2024 |
- |
$0.066667 |
- |
2024-05-16 |
- |
Stock split |
Total Amount for 2024: $0.066667 |
2023 |
- |
$0.062500 |
- |
2023-03-14 |
- |
Stock split |
Total Amount for 2023: $0.062500 |
📅 Earnings & EPS History for Dermata Therapeutics, Inc.
Date | Reported EPS |
---|
2025-08-13 | -1.66 |
2025-05-14 | -4.5 |
2025-03-17 | -13.4 |
2024-11-13 | -20.4 |
2024-08-07 | -41.8 |
2024-05-15 | -4.7 |
2024-03-21 | -31.5 |
2023-11-09 | -81 |
2023-08-10 | -94.5 |
2023-05-11 | -340.5 |
2023-02-21 | -288 |
2022-11-10 | -480 |
2022-08-15 | -576 |
2022-05-16 | -792 |
2022-03-28 | -1944 |
2021-11-15 | -2064 |
2021-09-27 | -1680 |
📰 Related News & Research
No related articles found for "dermata therapeutics".